Ignite Creation Date:
2024-06-16 @ 11:50 AM
Last Modification Date:
2024-10-26 @ 3:31 PM
Study NCT ID:
NCT06445582
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-06-06
First Post:
2024-05-22
Brief Title:
SV2A-PETCT and PETMRI Combined Clinical Criteria Score in the Diagnosis of Early Cognitive Alteration
Sponsor:
Anhui Provincial Hospital
Organization:
Anhui Provincial Hospital
Study Overview
Official Title:
Synaptic Vesicle Glycoprotein 2A-PETCT and PETMRI Combined Clinical Criteria Score in the Diagnosis of Early Cognitive Alteration
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Using SV2A-PET to character a cohort of patients with early cognitive impairment using the novel synaptic probe 18F-labeled difluoro-analog of UCB-Jalso known as 18F-SDM-8
Detailed Description:
A community-based population Han Chinese in Hefei China based on the CANDI cohortSingle-center prospective case-control studyThe projected enrollment population is 80 40 patients with Alzheimers DiseaseAD 30 patients with Mild Cognitive ImpairmentMCI 10 healthy controls Diagnostic experiments and predictive prognostic experiments with new probes
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None